SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

Perturbations of the circadian clock are linked to multiple diseases, including cancers. Pharmacological activation of REV-ERB nuclear receptors, the core components of the circadian clock, has antitumor effects on various malignancies, while the impact of SR9009 on prostate cancer (PCa) remains unk...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hang, Zhang, Jiapeng, Zheng, Xiaonan, Tan, Ping, Xiong, Xingyu, Yi, Xianyanling, Yang, Yang, Wang, Yan, Liao, Dazhou, Li, Hong, Wei, Qiang, Ai, Jianzhong, Yang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649669/
https://www.ncbi.nlm.nih.gov/pubmed/36357378
http://dx.doi.org/10.1038/s41419-022-05392-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649669/
https://www.ncbi.nlm.nih.gov/pubmed/36357378
http://dx.doi.org/10.1038/s41419-022-05392-6

Ejemplares similares